Omeros Corporation is in the biotechnology industry and is in the healthcare sector. The company CEO is Gregory A. Demopulos. Omeros Corp is a biopharmaceutical company. It focuses on research and development of small-molecule and protein therapeutics to treat inflammation, coagulopathies, and disorders of the central nervous system and sells Omidria for cataract surgeries.



Previous Intraday Performance:

The OMER shares had a previous change of 2.37% which opened at 18.52 and closed at 18.99. It moved to an intraday high of 19.00 and a low of 18.37.

Business Wire:  Omeros to Present at the UBS Global Healthcare Conference

Historical Performance:

Over the last five trading days, OMER shares returned 2.32% and in the past 30 trading days it returned 4.92%. Over three months, it changed 36.62%. In one year it has changed -5.10% and within that year its 52-week high was 27.00 and its 52-week low was 10.30. OMER stock is 84.37% above its 52 Week Low.

Our calculations result in a 200 day moving average of 16.99 and a 50 day moving average of 17.91. Right now, OMER stock is trading 11.75% above its 200 day moving average.

Business Wire:  Omeros to Present at the UBS Global Healthcare Conference

Liquidity:

The company has a market cap of $931.6m with 49.1m shares outstanding and a float of 46.5m shares. Trading volume was 295,113 shares and has experienced an average volume of 427,342 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Omeros Corporation was -2.61 which ended on 31st of December 2018. Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.12.

The next earnings report will be: 05-31-2019

The growth of the EPS is critical in understanding the current valuation of Omeros Corporation; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been -13.10% over the last twelve months.

Indicators Also to Watch:

Based on the latest filings, there is 63.30% of institutional ownership.



I calculated the beta to be 3.51

SeekingAlpha:  Onconova Therapeutics misses by $0.26, misses on revenue

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -127.23%, price-to-sales is 18.18 and price-to-book is 8.50.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 1  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here